EXTENDING HEALTHY HUMAN LIFESPAN
Zylem develops cancer, ocular and cardiovascular disease therapeutics, as well as anti-aging treatments for mitochondrial restoration. These applications are based on its portfolio of novel metabolic redox modulators.
Zylem’s Metabolic Redox Modulators (MRMs) are tunable mimics of natural molecules modeled on high-density lipoproteins (HDLs) that target SR-B1. Until now, SR-B1 was a known but undruggable target. MRMs tightly bind SR-B1, modulate oxidative stress and inflammation, thus resulting in potent killing of cancer cells and regulation of cellular damage in heart disease and dermatological conditions.
Our MRMs are designed to induce “Metabolic Checkmate”. MRMs regulate three hallmarks of cancer in one shot: enhance immune destruction, reduce tumor promoting inflammation, and induce cancer cell death by enhancing oxidative stress.
